Tesla operates as an electric vehicle and clean energy company. The business structure consists of various departments such as manufacturing, engineering, research and development, sales, and service. Tesla focuses on vertical integration, performing many functions in-house, from battery production to vehicle assembly. The company has a centralized decision-making process, with Elon Musk as the CEO overseeing overall strategy and leadership. Tesla operates its manufacturing facilities in different locations, including the United States and China, to cater to global demand. Additionally, the company has a direct-to-consumer sales model, bypassing traditional dealership networks, allowing for a more streamlined customer experience. It will definitely rise above $300 before its earning becaus
$IPS SECUREX HOLDINGS LIMITED(42N.SI)$ This company recently swing their business into handling major Data Centre Projects with remarkable potential in the security business! Despite maintaining low profile, they have managed to establish an impressive presence within the Security industry In Singapore. Their dedication towards providing top-notch security solutions with utmost discretion sets them apart. Their innovative approach and commitment to excellence, will continue to flourish and achieve great heights in the security industry for being a local SME. I also notice that they have swing their solutions into providing cloud based AI video surveillance to help their customer to manage their system with lesser headaches.
On Aug. 12, the FDA updated the Emergency Use Authorizations (EUAs) for the COVID-19 vaccines made by Pfizer (NYSE:PFE) along with its partner, BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) to include a third booster dose for immunocompromised individuals. One day later, the CDC changed its stance to recommend booster doses of the two messenger RNA (mRNA) vaccines for moderately to severely immunocompromised individuals. With EUAs in hand for third booster doses, will the top COVID-19 vaccine makers rake in a lot more revenue now? Not really. Here's why Pfizer and Moderna won't make as much extra money from U.S. booster doses as you might think.One key reason why Pfizer and Moderna won't make much more money is the limited scope of the EUA expansions. The FDA said that the broader auth
Why Pfizer and Moderna Won't Make As Much Extra Money ?
Key PointsThe FDA and CDC have given a thumbs-up for third booster doses of mRNA vaccines in immunocompromised individuals, but this won't translate to a lot of extra revenue for Pfizer or Moderna.There's a relatively small market in the U.S. for booster doses under the current EUAs.The U.S. government has also already secured supply deals for more than enough doses to fully vaccinate every American and give a third booster dose.On Aug. 12, the FDA updated the Emergency Use Authorizations (EUAs) for the COVID-19 vaccines made by Pfizer (NYSE:PFE) along with its partner, BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) to include a third booster dose for immunocompromised individuals. One day later, the CDC changed its stance to recommend booster doses of the two messenger RNA (mRNA) vacci
The Fed's lending practices have supported the economy in its road to recovery, and the economy has rebounded from the early, dark days of the coronavirus pandemic. But as a result of the pandemic, American and Asia industry has faced a combination of labor shortages, supply chain constraints and higher consumer demand. These, along with stimulative federal spending packages, have led to rising inflation concerns for investors, with the added complication of potential deceleration of economic growth."A real risk investors might be missing right now is the risk of stagflation, or the persistent increase in price pressures alongside slowing economic growth.”What do you think?